Van ECK Associates Corp Decreases Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Van ECK Associates Corp reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.9% in the second quarter, according to its most recent filing with the SEC. The fund owned 24,601 shares of the company’s stock after selling 2,109 shares during the quarter. Van ECK Associates Corp’s holdings in IDEXX Laboratories were worth $12,951,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SHP Wealth Management bought a new position in IDEXX Laboratories during the fourth quarter valued at $26,000. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories in the 3rd quarter worth about $26,000. J.Safra Asset Management Corp bought a new stake in shares of IDEXX Laboratories in the 2nd quarter worth about $25,000. Elevation Wealth Partners LLC raised its position in shares of IDEXX Laboratories by 188.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after buying an additional 32 shares in the last quarter. Finally, Wormser Freres Gestion raised its position in shares of IDEXX Laboratories by 671.4% during the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 47 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Price Performance

IDXX stock opened at $556.69 on Tuesday. The stock has a market cap of $43.86 billion, a PE ratio of 39.15, a P/E/G ratio of 2.96 and a beta of 1.54. IDEXX Laboratories, Inc. has a 12 month low of $518.55 and a 12 month high of $769.98. The company has a 50-day moving average price of $559.23 and a 200 day moving average price of $572.70. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the prior year, the company posted $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Analysts Set New Price Targets

IDXX has been the subject of several recent research reports. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Citigroup upped their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. UBS Group raised their price objective on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday. Finally, Barclays cut their target price on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $747.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.